CND261

BIOLOGICAL2 trials

Sponsors

Fraunhofer Institute For Translational Medicine And Pharmacology ITMP, Candid Therapeutics

Conditions

ANCA-IgG-positive associated vasculitisActiveRheumatoid Arthritistreatment refractory

Phase 1

An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis

Active, not recruitingNCT07052032

Candid TherapeuticsRheumatoid Arthritis

Start: 2025-06-16End: 2027-06-01Target: 47Updated: 2026-09-03

An open label, phase I/II study investigating the safety and efficacy of a CD3/CD20 bispecific T-cell engager therapy in patients with active, treatment refractory, ANCA-IgG-positive associated vasculitis. The RENEWAL study

Not yet recruitingCTIS2025-522853-21-01

Fraunhofer Institute For Translational Medicine And Pharmacology ITMPActive, ANCA-IgG-positive associated vasculitis, treatment refractory

Target: 8Updated: 2026-01-30